David Hackshall - Cochlear Chief Officer

OC5 Stock  EUR 120.00  4.00  3.23%   

Insider

David Hackshall is Chief Officer of Cochlear Limited
Address 1 University Avenue, Sydney, NSW, Australia, 2109
Phone61 2 9428 6555
Webhttps://www.cochlear.com

Cochlear Management Efficiency

The company has return on total asset (ROA) of 0.1128 % which means that it generated a profit of $0.1128 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1815 %, meaning that it generated $0.1815 on every $100 dollars invested by stockholders. Cochlear's management efficiency ratios could be used to measure how well Cochlear manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cochlear's Non Currrent Assets Other are most likely to increase significantly in the upcoming years. The Cochlear's current Other Current Assets is estimated to increase to about 6.1 M, while Total Assets are projected to decrease to roughly 2.2 B.
Cochlear Limited has accumulated 874.7 M in total debt with debt to equity ratio (D/E) of 25.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Cochlear Limited has a current ratio of 1.81, which is within standard range for the sector. Debt can assist Cochlear until it has trouble settling it off, either with new capital or with free cash flow. So, Cochlear's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cochlear Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cochlear to invest in growth at high rates of return. When we think about Cochlear's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

INSIDER Age

Stephana PattonBIOTIME
48
Oliver OlbrichTELES Informationstechnologien
59
Michael MulroyBIOTIME
53
Don BaileyBIOTIME
73
Alfred KingsleyBIOTIME
76
Deborah AndrewsBIOTIME
61
Alexandra HernandezBIOTIME
N/A
Edward WirthBIOTIME
53
Stephen FarrellBIOTIME
54
Angus RussellBIOTIME
63
Chase LeavittBIOTIME
37
Gary HoggeBIOTIME
51
Neal BradsherBIOTIME
53
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Cochlear Limited was incorporated in 1983 and is headquartered in Sydney, Australia. COCHLEAR LTD operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 3500 people. Cochlear Limited (OC5) is traded on Frankfurt Exchange in Germany and employs 5,500 people. Cochlear is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Cochlear Limited Leadership Team

Elected by the shareholders, the Cochlear's board of directors comprises two types of representatives: Cochlear inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cochlear. The board's role is to monitor Cochlear's management team and ensure that shareholders' interests are well served. Cochlear's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cochlear's outside directors are responsible for providing unbiased perspectives on the board's policies.
Karen ODriscoll, Chief Officer
Stuart Sayers, President America
Dean Phizacklea, Senior Marketing
Jennifer Hornery, Senior Culture
Richard MBA, Pres EMEA
Jan Eng, Chief Officer
Jennifer Stevenson, VP Brand
Sarah Thom, Chief Officer
Rob McGrory, Group Secretary
Kristina Devon, VP Relations
Lisa Aubert, Pres America
MBA BE, MD, CEO
David Hackshall, Chief Officer
Anthony Bishop, Pres America

Cochlear Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cochlear a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Cochlear Stock

Cochlear financial ratios help investors to determine whether Cochlear Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cochlear with respect to the benefits of owning Cochlear security.